Dr James McIlroy

24 September 2018

QIB Lecture Theatre

Faecal Microbiota Transplantation (FMT) - novel approaches to an ancient therapeutic strategy

Speaker: Dr James McIlroy, Founder and CEO, EnteroBiotix Ltd, Aberdeen, will present a seminar entitled: Faecal Microbiota Transplantation (FMT) – novel approaches to an ancient therapeutic strategy

James McIlroyHost: Christian Roghi

Faecal Microbiota Transplantation (also known as a stool transplant or FMT) is a therapeutic modality that clinicians implement to treat patients suffering from diseases associated with imbalances of bacteria in the intestinal tract. It is a National Institute for Health and Care Excellence (NICE) approved treatment for recurrent C.difficile infection (CDI) with cure rates of ~90% reported widely across the medical literature.

FMT has also shown promise in clinical trials for disease indications beyond CDI such as Inflammatory Bowel Disease. There is growing clinical and patient demand for FMT, which is currently thought to be underserviced as doctors have to screen donors and process samples themselves.

Dr James McIlroy identified these challenges as a medical student and set up a company, called EnteroBiotix, to solve those problems. He raised over £2m of funding for EnteroBiotix while at medical school and under his leadership, the company became the first in the world to be awarded a license from the Medicines and Healthcare Products Regulatory Agency (MHRA) to manufacture faecal microbiota for therapeutic application in FMT. James now works as a part-time NHS junior doctor alongside his duties at EnteroBiotix and is leading a number of exciting and innovative programmes at the company.

This seminar is focussed on three things:

a) Up to date information and evidence on the use of faecal microbiota transplantation in recurrent CDI and other diseases/infections
b) His experiences in building a biotechnology company and establishing MHRA licensed faecal microbiota manufacturing capabilities
c) Future perspectives on microbiome modulating therapeutics.


All staff from organisations on the Norwich Research Park are welcome to attend.